Single-anastomosis duodenal-ileal bypass with sleeve gastrectomy for diabetes: predictors of remission and metabolic outcomes in a multicenter study
View abstract on PubMed
Summary
This summary is machine-generated.Single-anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S) effectively treats obesity and type 2 diabetes, achieving significant weight loss and remission. Higher BMI and insulin use predict poorer remission outcomes.
Area Of Science
- Metabolic and Bariatric Surgery
- Endocrinology
- Obesity Medicine
Background
- The single-anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S) integrates restrictive sleeve gastrectomy (SG) with the hypoabsorptive benefits of gastric bypass.
- SADI-S has shown promising results in terms of weight loss and surgical feasibility.
Purpose Of The Study
- To assess the efficacy of SADI-S in managing obesity and type 2 diabetes mellitus.
- To identify predictors of type 2 diabetes remission following SADI-S.
Main Methods
- A multicenter retrospective review of 419 adult patients with obesity and type 2 diabetes who underwent SADI-S between 2013 and 2023.
- Type 2 diabetes remission defined as HbA1C <6.5% without antidiabetic medication.
- Analysis of demographic, bariatric, and metabolic parameters.
Main Results
- Mean BMI was 47.1 kg/m², with a mean total weight loss of 31.9% over a 2.0-year follow-up.
- A 60.1% type 2 diabetes remission rate was observed.
- Preoperative insulin use and higher BMI negatively predicted remission; greater weight loss positively correlated with remission.
Conclusions
- SADI-S is a durable and effective metabolic and bariatric surgery for individuals with obesity and type 2 diabetes.
- Predictors for successful type 2 diabetes remission include lower preoperative BMI and absence of insulin use.

